Profile data is unavailable for this security.
About the company
Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
- Revenue in EUR (TTM)28.41m
- Net income in EUR-19.95m
- Incorporated2002
- Employees145.00
- LocationMedincell SA3 rue des Freres LumiereJACOU 34830FranceFRA
- Phone+33 467021367
- Websitehttps://www.medincell.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Procter & Gamble Health Ltd | 126.15m | 27.46m | 779.47m | 1.33k | 28.42 | -- | 26.34 | 6.18 | 176.64 | 176.64 | 811.45 | -- | -- | -- | -- | 10,169,760.00 | -- | -- | -- | -- | 72.49 | -- | 21.76 | -- | -- | 806.81 | -- | -- | -- | -- | -- | -- | -- | -- |
| Industri Jamu dn Frms Sd Mncl Tbk PT | 202.39m | 60.97m | 792.67m | 3.56k | 12.92 | 4.54 | 11.90 | 3.92 | 40.62 | 40.62 | 134.92 | 115.65 | 1.05 | 3.17 | 5.99 | 1,128,331,000.00 | 31.51 | 27.62 | 33.97 | 31.69 | 58.69 | 56.70 | 30.13 | 28.98 | 5.29 | -- | 0.0005 | 97.08 | 9.90 | 5.02 | 23.18 | 7.71 | -19.12 | 9.91 |
| Beijing Tong Ren Tang Chinese Medicine | 185.60m | 55.97m | 793.72m | 789.00 | 14.18 | 1.81 | 11.64 | 4.28 | 0.6157 | 0.6157 | 2.04 | 4.81 | 0.3878 | 0.4134 | 4.92 | 2,185,246.00 | 12.14 | 15.34 | 13.34 | 17.17 | 63.00 | 68.94 | 31.29 | 39.16 | 11.43 | -- | 0.0327 | 52.52 | 5.69 | 2.38 | -7.42 | -2.09 | 20.50 | 8.76 |
| Medincell SA | 28.41m | -19.95m | 800.78m | 145.00 | -- | -- | -- | 28.19 | -0.6143 | -0.6143 | 0.8982 | -0.9254 | 0.4258 | -- | 28.18 | 202,907.10 | -29.90 | -51.18 | -50.21 | -133.26 | 56.60 | 82.68 | -70.22 | -210.68 | -- | -0.9935 | 2.11 | -- | 181.43 | 54.88 | 26.36 | -- | 13.30 | -- |
| Jeena Sikho Lifecare Ltd | -935.51m | -935.51m | 802.13m | 3.76k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 32.29 | -- | 40.74 | -- | 92.07 | -- | 16.78 | -- | -- | -- | -- | 44.59 | 37.80 | 31.10 | 73.77 | 47.62 | -- |
| Pacira Biosciences Inc | 608.41m | 18.20m | 810.04m | 790.00 | 49.79 | 1.37 | 8.49 | 1.33 | 0.4664 | 0.4664 | 15.70 | 16.93 | 0.5085 | 1.11 | 6.64 | 907,330.40 | 1.52 | 1.87 | 1.78 | 2.22 | 79.17 | 73.06 | 2.99 | 4.84 | 3.78 | -- | 0.3413 | 0.00 | 3.85 | 10.73 | -337.30 | -- | 0.9219 | -- |
| Beijing Konruns Pharmaceutical Co Ltd | 107.05m | 7.02m | 823.44m | 668.00 | 119.92 | 2.10 | -- | 7.69 | 0.3515 | 0.3515 | 5.55 | 20.06 | 0.2166 | 1.58 | 2.86 | 1,304,353.00 | 0.8033 | 3.82 | 0.9658 | 4.45 | 89.11 | 88.68 | 3.71 | 16.16 | 2.98 | -- | 0.0745 | 31.72 | -10.28 | -4.99 | -71.94 | -30.80 | 40.67 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Mirova SA (Investment Management)as of 30 Jun 2025 | 2.46m | 7.37% |
| Polar Capital LLPas of 22 Jan 2026 | 1.67m | 5.01% |
| Adage Capital Management LPas of 30 Jun 2025 | 1.26m | 3.78% |
| Syquant Capital SASas of 30 Jun 2025 | 923.76k | 2.77% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 755.32k | 2.27% |
| CPR Asset Management SAas of 31 Dec 2025 | 554.14k | 1.66% |
| Amundi Asset Management SASU (Investment Management)as of 31 Dec 2025 | 437.89k | 1.31% |
| AXA Investment Managers (Paris) SAas of 30 Jan 2026 | 363.21k | 1.09% |
| Saint Olive Gestion SNCas of 31 Dec 2025 | 339.05k | 1.02% |
| Montpensier Arbevel SASas of 30 Jun 2025 | 298.30k | 0.90% |
